143 related articles for article (PubMed ID: 30508971)
1. Long-term clinical response of advanced lung adenocarcinoma to maintenance treatment of gemcitabine: A case report.
Lv X; Gou F; Shen Y; Lu H; Chen J; Liu J; Chen H; Zhang X; Yu D
Medicine (Baltimore); 2018 Nov; 97(48):e13464. PubMed ID: 30508971
[TBL] [Abstract][Full Text] [Related]
2. Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer: IFCT-1201 MODEL trial.
Quoix E; Audigier-Valette C; Lavolé A; Molinier O; Westeel V; Barlesi F; Le Treut J; Pichon E; Dauba J; Otto J; Moreau L; Madelaine J; Dumont P; Margery J; Debieuvre D; Renault PA; Pujol JL; Langlais A; Morin F; Moro-Sibilot D; Souquet PJ
Eur J Cancer; 2020 Oct; 138():193-201. PubMed ID: 32898792
[TBL] [Abstract][Full Text] [Related]
3. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer.
Pérol M; Chouaid C; Pérol D; Barlési F; Gervais R; Westeel V; Crequit J; Léna H; Vergnenègre A; Zalcman G; Monnet I; Le Caer H; Fournel P; Falchero L; Poudenx M; Vaylet F; Ségura-Ferlay C; Devouassoux-Shisheboran M; Taron M; Milleron B
J Clin Oncol; 2012 Oct; 30(28):3516-24. PubMed ID: 22949150
[TBL] [Abstract][Full Text] [Related]
4. Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: results by performance status, EGFR mutation, histology and response to previous induction.
Tan PS; Lopes G; Acharyya S; Bilger M; Haaland B
Eur J Cancer; 2015 Nov; 51(16):2330-44. PubMed ID: 26364517
[TBL] [Abstract][Full Text] [Related]
5. When less is better: the safety and efficacy of reduced intensity gemcitabine in a difficult patient population with advanced non-small-cell lung cancer.
Nacci A; Calvani N; Rizzo P; Fedele P; Orlando L; Schiavone P; Cinefra M; Marino A; Sponziello F; D'Amico M; Cinieri S
Med Oncol; 2013 Mar; 30(1):370. PubMed ID: 23322519
[TBL] [Abstract][Full Text] [Related]
6. Real world experience on maintenance chemotherapy with gemcitabine in second line setting for advanced non-small cell lung carcinoma.
Kwok WC; Lam DCL; Chiang KY; Ho JCM; Ip MSM; Tam TCC
J Chemother; 2020 Dec; 32(8):429-436. PubMed ID: 33043860
[TBL] [Abstract][Full Text] [Related]
7. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE
Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
Cobo Dols M; Villar Chamorro E; Alés Díaz I; Gil Calle S; Alcalde García J; Gutiérrez Calderón V; Carabantes Ocón F; Montesa Pino A; Bretón García JJ; Benavides Orgaz M
Clin Transl Oncol; 2006 Oct; 8(10):742-9. PubMed ID: 17074673
[TBL] [Abstract][Full Text] [Related]
9. Pemetrexed plus platinum or gemcitabine plus platinum for advanced non-small cell lung cancer: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis.
Zhang X; Lu J; Xu J; Li H; Wang J; Qin Y; Ma P; Wei L; He J
Respirology; 2013 Jan; 18(1):131-9. PubMed ID: 22882698
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine, cisplatin, and hyperfractionated accelerated radiotherapy for locally advanced non-small cell lung cancer.
Zwitter M; Kovac V; Smrdel U; Strojan P
J Thorac Oncol; 2006 Sep; 1(7):662-6. PubMed ID: 17409933
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.
Gatzemeier U; Groth G; Butts C; Van Zandwijk N; Shepherd F; Ardizzoni A; Barton C; Ghahramani P; Hirsh V
Ann Oncol; 2004 Jan; 15(1):19-27. PubMed ID: 14679114
[TBL] [Abstract][Full Text] [Related]
12. Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer.
ten Bokkel Huinink WW; Bergman B; Chemaissani A; Dornoff W; Drings P; Kellokumpu-Lehtinen PL; Liippo K; Mattson K; von Pawel J; Ricci S; Sederholm C; Stahel RA; Wagenius G; Walree NV; Manegold C
Lung Cancer; 1999 Nov; 26(2):85-94. PubMed ID: 10568679
[TBL] [Abstract][Full Text] [Related]
13. Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study.
Borget I; Pérol M; Pérol D; Lavolé A; Greillier L; Dô P; Westeel V; Crequit J; Léna H; Monnet I; Le Caer H; Fournel P; Falchero L; Poudenx M; Vaylet F; Chabaud S; Vergnenegre A; Zalcman G; Chouaïd C;
BMC Cancer; 2014 Dec; 14():953. PubMed ID: 25511923
[TBL] [Abstract][Full Text] [Related]
14. Weekly gemcitabine and monthly cisplatin for advanced non-small cell lung carcinoma.
Abratt RP; Hacking DJ; Goedhals L; Bezwoda WR
Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-18-S8-23. PubMed ID: 9207311
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC).
Yang J; He J; Yu M; Li T; Luo L; Liu P
Medicine (Baltimore); 2016 Dec; 95(50):e5599. PubMed ID: 27977596
[TBL] [Abstract][Full Text] [Related]
16. Long-term survival of advanced lung adenocarcinoma by maintenance chemotherapy followed by EGFR-TKI: A case report.
Chen HJ; Shen JM; Lin YN; Du W; Zhou JP; Li QY
Medicine (Baltimore); 2021 Feb; 100(6):e24688. PubMed ID: 33578601
[TBL] [Abstract][Full Text] [Related]
17. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
Wu YL; Zhou C; Hu CP; Feng J; Lu S; Huang Y; Li W; Hou M; Shi JH; Lee KY; Xu CR; Massey D; Kim M; Shi Y; Geater SL
Lancet Oncol; 2014 Feb; 15(2):213-22. PubMed ID: 24439929
[TBL] [Abstract][Full Text] [Related]
18. [Non-small cell lung cancer with liver metastasis responsive to gemcitabine--a case report].
Sakurai T; Oura S; Yoshimasu T; Tanino H; Kokawa Y; Nakamura T; Matsuyama K; Naito Y
Gan To Kagaku Ryoho; 2001 May; 28(5):707-10. PubMed ID: 11383223
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study.
Bylicki O; Ferlay C; Chouaid C; Lavolé A; Barlési F; Dubos C; Westeel V; Créquit J; Corre R; Vergnenègre A; Monnet I; Le Caer H; Fournel P; Vaylet F; Falchero L; Poudenx M; Linard P; Pérol D; Zalcman G; Pérol M
J Thorac Oncol; 2013 Jul; 8(7):906-14. PubMed ID: 23591160
[TBL] [Abstract][Full Text] [Related]
20. Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin.
Hyung J; Kim B; Yoo C; Kim KP; Jeong JH; Chang HM; Ryoo BY
Cancer Res Treat; 2019 Jul; 51(3):901-909. PubMed ID: 30282446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
